For questions about BMS medicines during this time, please call 1-800-721-8909.
On Call ORENCIA® (abatacept) support program logo

For your patients, including your dual-seropositive patients (anti-CCP+ and RF+), once you have prescribed ORENCIA.

For your patients, including your dual-seropositive patients (anti-CCP+ and RF+), once you have prescribed ORENCIA.

We are committed to helping your ORENCIA IV & SC patients access the treatment you have
chosen for them with coverage assistance and financial support. Start by enrolling them below.

We are committed to helping your ORENCIA IV & SC patients access the treatment you have
chosen for them with coverage assistance and financial support. Start by enrolling them below.

Coverage assistance

Assistance with benefits verification,
prior authorization (PA), and appeals.

Commence Rx
helps SC patients get started

Commence Rx can help eligible first-time ORENCIA patients get
started—at no cost—during the
coverage determination process.*


Financial support

Example of an ORENCIA Co-pay Assistance Card

Terms and Conditions apply.

For SC co-pay assistance,
your patients enroll themselves

By calling 1-800-ORENCIA
(1-800-673-6242)
or visiting ORENCIA.com.


For IV co-pay assistance,
provider requests on enrollment form

Digitally at ORENCIAportal.com
or by faxing the enrollment form
to 866-268-5385.


Enrollment

Get your patients started with:

1 digital portal for your IV and SC patients

With electronic PA capability

OR

1 paper form to enroll your
IV and SC patients

Fax to 866-268-5385

Patients can sign their Patient Authorization Agreement in office or after their visit at ORENCIA.com/sign.

Call 1-800-ORENCIA
(1-800-673-6242)

for any assistance.

Have your patients call this number if
their pharmacy does not accept their co-pay card.

*Eligibility requirements and Terms and Conditions apply.


More patients, including dual-seropositive (anti-CCP+ and RF+) patients, are now covered

IMPROVED
COVERAGE
IN 2021*

moderate to severe rheumatoid arthritis patient moderate to severe rheumatoid arthritis patient

BSE, biologic step edit.
*Compared to access in 2018.

ORENCIA SC

Commercial formulary coverage
1st-line access

  • CVS CAREMARK
  • AETNA

2 BSEs

  • Express Scripts
  • Optum Rx
  • United Healthcare


ORENCIA IV

94% coverage through Medicare

BSE, biologic step edit.
*Compared to access in 2018.

anti-CCP, anti-cyclic citrullinated peptide; RF, rheumatoid factor.


Patient education and resources

The ORENCIA On Call™ patient support program offers a host of services, including help with insurance,
co-pay assistance, and nurse support*

Personal ORENCIA Care Counselor*

Available 24/7

ORENCIA nurse support*

Available 24/7

Help with insurance

Help with questions about coverage and co-pay costs for ORENCIA

ORENCIA injection instructions

How-to instructions to help patients
administer their treatment

Educational materials

Information for your patients

Sharps disposal

Free disposal of used syringes

*Care Counselors and nurse support can provide general information about ORENCIA but may not provide medical advice.

ORENCIA nurses are available Monday through Friday from 8 am to 8 pm ET. At all other times, nurses will usually return calls within 30 to 60 minutes. The nurse cannot provide medical advice. Response times may vary in Puerto Rico.

Important Safety Information
for ORENCIA® (abatacept)

Concomitant Use with TNF Antagonists, Other Biologic RA/PsA Therapy, or JAK Inhibitors: Concurrent therapy with ORENCIA and a TNF antagonist is not recommended. In controlled clinical trials, adult RA patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections (63% vs 43%) and serious infections (4.4% vs 0.8%) compared to patients treated with only TNF antagonists, without an important enhancement of efficacy. Additionally, concomitant use of ORENCIA with other biologic RA/PsA therapy or JAK inhibitors is not recommended.

Hypersensitivity: There were 2 cases (<0.1%; n=2688) of anaphylaxis reactions in clinical trials with adult RA patients treated with intravenous ORENCIA. Other reactions potentially associated with drug hypersensitivity, such as hypotension, urticaria, and dyspnea, each occurred in <0.9% of patients. There was one case of a hypersensitivity reaction with ORENCIA in pJIA clinical trials (0.5%; n=190). In postmarketing experience, fatal anaphylaxis following the first infusion of ORENCIA and life-threatening cases of angioedema have been reported. Angioedema has occurred as early as after the first dose of ORENCIA, but also has occurred with subsequent doses. Angioedema reactions have occurred within hours of administration and in some instances had a delayed onset (i.e., days). Appropriate medical support measures for treating hypersensitivity reactions should be available for immediate use. If an anaphylactic or other serious allergic reaction occurs, administration of intravenous or subcutaneous ORENCIA should be stopped immediately and permanently discontinued, with appropriate therapy instituted.

Infections: Serious infections, including sepsis and pneumonia, were reported in 3% and 1.9% of RA patients treated with intravenous ORENCIA and placebo, respectively. Some of these infections have been fatal. Many of the serious infections have occurred in patients on concomitant immunosuppressive therapy which, in addition to their underlying disease, could further predispose them to infection. Caution should be exercised in patients with a history of infection or underlying conditions which may predispose them to infections. Treatment with ORENCIA should be discontinued if a patient develops a serious infection. Patients should be screened for tuberculosis and viral hepatitis in accordance with published guidelines, and if positive, treated according to standard medical practice prior to therapy with ORENCIA.

Immunizations: Prior to initiating ORENCIA in pediatric and adult patients, update vaccinations in accordance with current vaccination guidelines. Live vaccines should not be given concurrently with ORENCIA or within 3 months after discontinuation. ORENCIA may blunt the effectiveness of some immunizations.

Use in Patients with Chronic Obstructive Pulmonary Disease (COPD): In Study V, adult COPD patients treated with ORENCIA for RA developed adverse events more frequently than those treated with placebo, including COPD exacerbations, cough, rhonchi, and dyspnea. In the study, 97% of COPD patients treated with ORENCIA developed adverse events versus 88% treated with placebo. Respiratory disorders occurred more frequently in patients treated with ORENCIA compared to those on placebo (43% vs 24%, respectively), including COPD exacerbation, cough, rhonchi, and dyspnea. A greater percentage of patients treated with ORENCIA developed a serious adverse event compared to those on placebo (27% vs 6%), including COPD exacerbation [3 of 37 patients (8%)] and pneumonia [1 of 37 patients (3%)]. Use of ORENCIA in patients with COPD should
be undertaken with caution, and such
patients monitored for worsening of their respiratory status.

Immunosuppression: In clinical trials in adult RA patients, a higher rate of infections was seen in ORENCIA-treated patients compared to placebo-treated patients. The impact of treatment with ORENCIA on the development and course of malignancies is not fully understood. There have been reports of malignancies, including skin cancer in
patients receiving ORENCIA. Periodic skin examinations are recommended for all ORENCIA-treated patients, particularly those with risk factors for skin cancer.

Blood Glucose Testing: ORENCIA for intravenous administration contains maltose, which may result in falsely elevated blood glucose readings on the day of infusion when using blood glucose monitors with test strips utilizing glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ). Consider using monitors and advising patients to use monitors that do not react with maltose, such as those based on glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase or glucose hexokinase test methods. ORENCIA for subcutaneous (SC) administration does not contain maltose; therefore, patients do not need to alter their glucose monitoring.

Pregnancy: There are no adequate and well-controlled studies of ORENCIA use in pregnant women and the data with ORENCIA use in pregnant women are insufficient to inform on drug-associated risk. A pregnancy registry has been established to monitor pregnancy outcomes in women exposed to ORENCIA during pregnancy. Healthcare professionals are encouraged to register patients by calling 1-877-311-8972.

Lactation: There is no information regarding the presence of abatacept in human milk, the effects on the breastfed infant, or the effects on milk production. However, abatacept was present in the milk of lactating rats dosed with abatacept.

Most Serious Adverse Reactions: Serious infections (3% ORENCIA vs 1.9% placebo) and malignancies (1.3% ORENCIA vs 1.1% placebo).

Malignancies: The overall frequency of malignancies was similar between adult RA patients treated with ORENCIA or placebo. However, more cases of lung cancer were observed in patients treated with ORENCIA (0.2%) than those on placebo (0%). A higher rate of lymphoma was seen compared to the general population; however, patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of ORENCIA in the development of malignancies in humans is unknown.

Most Frequent Adverse Events (≥10%): Headache, upper respiratory tract infection, nasopharyngitis, and nausea were the most commonly reported adverse events in the adult RA clinical studies. Other events reported in ≥5% of pJIA patients were diarrhea, cough, pyrexia, and abdominal
pain. In general, the adverse events in pediatric pJIA and adult PsA patients were similar in frequency and type to those seen in adult RA patients.

Note concerning ORENCIA administration options: ORENCIA may be administered as an intravenous infusion only for patients 6 years of age and older. PJIA patients may self-inject with ORENCIA or the patient’s caregiver may administer ORENCIA if both the healthcare practitioner and the parent/legal guardian determines it is appropriate. The ability of pediatric patients to self-inject with the autoinjector has not been tested.

Please click here for Full Prescribing Information